FMP
Vincerx Pharma, Inc.
VINC
NASDAQ
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
0.73 USD
-0.1667 (-22.84%)
About
ceo
Dr. Ahmed M. Hamdy M.D.
sector
Healthcare
industry
Biotechnology
website
https://vincerx.com
exchange
NASDAQ
Description
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
CIK
0001796129
ISIN
US92731L1061
CUSIP
92731L106
Address
260 Sheridan Avenue
Phone
650 800 6676
Country
US
Employee
42
IPO Date
May 27, 2020
Key Executives
